G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm

American Journal of Hematology

Volumn 90, Issue 4, 2015, Pages 295-300

  Becker, Pamela S ^a,b   Medeiros, Bruno C ^c   Stein, Anthony S ^d   Othus, Megan ^b   Appelbaum, Frederick R ^a,b   Forman, Stephen J ^d   Scott, Bart L ^a,b   Hendrie, Paul C ^a   Gardner, Kelda M ^a   Pagel, John M ^a,b   Walter, Roland B ^a,b   Parks, Cynthia ^a   Wood, Brent L ^e   Abkowitz, Janis L ^a   Estey, Elihu H ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYTARABINE; DEXAMETHASONE; FILGRASTIM; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; PREDNISONE; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ARTICLE; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; HYPOXIA; INFLUENZA; LEUKEMIA REMISSION; LUNG HEMORRHAGE; LUNG INFECTION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; FLOW CYTOMETRY; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; YOUNG ADULT;

ADENINE NUCLEOTIDES; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; YOUNG ADULT;

EID: 84925348505     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23927     Document Type: Article

References (24)

1. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108:45-51.
2. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-1645.
3. Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol 2012;30:2492-2499.
4. Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol 2011;155:182-189.
5. Becker PS, Kantarjian HM, Appelbaum FR, et al. Retrospective comparison of clofarabine versus fludarabine in combination with high dose cytarabine with or without G-CSF as salvage therapies for acute myeloid leukemia (AML). Haematologica 2013;98:114-118.
6. Cheson BD, Bennett JM, Kopecky KJ, et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-4649.
7. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
8. Wood BL. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol 2013;999:123-136.
9. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
10. Faderl S, Ravandi F, Huang X. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012;118:4471-4477.
11. Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 2014. doi: 10.1038/leu.2014.242. [Epub ahead of print] PMID: 25113226
12. Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 2013;122:1384-1394.
13. Ferrara F, Palmieri S, Pocali B, Pollio F, Viola A, Annunziata S, Sebastio L, Schiavone EM, Mele G, Gianfaldoni G, Leoni F. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 45 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002;68:203-209.
14. Borthakur G, Cortes JE, Estey EE, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 2014;89:964-968.
15. Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi VV, Raimondi SC, Downing JR, Razzouk BI, Pui CH, Ribeiro RC. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: Results of the St Jude AML97 trial. Leukemia 2009;23:1410-1416.
16. Borthakur G, Kantarjian H, Wang X, et al. Treatment of core-binding-factor in acute, myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating, factor results in improved event-free survival. Cancer 2008;113:3181-3185.
17. Gyurkocza B, Gutman J, Nemecek ER, et al. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant 2014;20:549-552.
18. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013;122:1813-1821.
19. Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013;31:3889-3897.
20. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-1259.
21. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-1248.
22. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854-4860.
23. Nazha A, Kantarjian H, Ravandi F, et al. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol 2013;88:961-966.
24. Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A final report of the Polish Adult Leukemia Group. Eur J Haematol 2008;80:115-126.